Characterizing New and Boosted HIV-Specific T-Cell Responses Elicited by an HIV Therapeutic Vaccine
Background: Little is known about the capacity of HIV therapeutic vaccines to overcome pre-existing immunodominance hierarchies and elicit functional, long-lived new or boosted HIV-specific CD8+ T cell responses. We previously reported therapeutic vaccine-induced new and boosted HIV-specific T cell responses in people with HIV on ART in the PENNVAX trial. We now characterize the magnitude,…